dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lopez-Bonet, Eugeni |
dc.contributor.author | Buxó, Maria |
dc.contributor.author | Cuyàs, Elisabet |
dc.contributor.author | Pernas, Sonia |
dc.contributor.author | Dorca, Joan |
dc.contributor.author | Álvarez, Isabel |
dc.contributor.author | Cortés Castan, Javier |
dc.date.accessioned | 2021-04-13T14:08:29Z |
dc.date.available | 2021-04-13T14:08:29Z |
dc.date.issued | 2019-12-11 |
dc.identifier.citation | Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, et al. Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. J Clin Med. 2019 Dec 11;8(12):2180. |
dc.identifier.issn | 2077-0383 |
dc.identifier.uri | https://hdl.handle.net/11351/5846 |
dc.description | Metformina; Ki67; Càncer de mama |
dc.description.sponsorship | This work was supported by Grants from the Ministerio de Sanidad, Servicios Sociales e Igualdad (EC10-125, Ayudas para el Fomento de la Investigación Clínica Independiente to Begoña Martin-Castillo). Work in the Menendez laboratory is supported by the Spanish Ministry of Science and Innovation (Grant SAF2016-80639-P, Plan Nacional de l+D+I, founded by the European Regional Development Fund, Spain) and by an unrestricted research grant from the Fundació Oncolliga Girona (Lliga catalana d’ajuda al malalt de càncer, Girona). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Journal of Clinical Medicine;8(12) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Metformina |
dc.subject | Mama - Càncer |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.title | Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/jcm8122180 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://www.mdpi.com/2077-0383/8/12/2180 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Lopez-Bonet E] Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona 17005, Spain. [Buxó M] Girona Biomedical Research Institute (IDIBGI), Girona 17190, Spain. [Cuyàs E] Girona Biomedical Research Institute (IDIBGI), Girona 17190, Spain. Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona 08908, Spain. [Pernas S] Department of Medical Oncology, Breast Unit, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona 08908, Spain. [Dorca J] Medical Oncology, Catalan Institute of Oncology, Girona 17005, Spain. [Álvarez I] Medical Oncology Service, Hospital Universitario Donostia, Donostia-San Sebastián 20014, Spain. Biodonostia Health Research Institute, Donostia-San Sebastián 20014, Spain. [Cortés J] IOB Institute of Oncology, Hospital Quirónsalud, Madrid & Barcelona 08023, Spain. Medica Scientia Innovation Researcher (MedSIR), Barcelona 08007, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 31835708 |
dc.identifier.wos | 000506640400150 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2016-80639-P |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |